Joseph D. Rosenblatt, M.D., is a Professor of Medicine, Chief of Hematology and Oncology and Associate Director for Clinical and Translational Research for the Sylvester Comprehensive Cancer Center (SCCC) at the University of Miami (UM). He holds a graduate cross appointment in the Department of Microbiology and Immunology at UM. Dr. Rosenblatt is also a member of the Tumor Immunology Program. In the past 20 years, Dr. Rosenblatt has published over 100 journal articles and chapters in the areas of human retroviruses, immune therapies for cancer, and human gene therapy. Dr. Rosenblatt's work has general relevance to breast cancer and he has held major breast cancer grant funding in the past. Prior to his move to Miami, Dr. Rosenblatt served as Chief of the Hematology-Oncology Unit, and had a secondary appointment within the Department of Microbiology and Immunology at the University of Rochester from 1995-2001. Prior to 1995, Dr. Rosenblatt had been a member of the faculty in Hematology Oncology (Associate Professor) and was elected an Associate Member of the Molecular Biology Institute at UCLA, California. Dr Rosenblatt joined University of Miami in 2001, bringing extensive administrative and research experience. He has had continuous NIH and other extramural funding for retroviral, gene therapy and immunotherapy related research since 1986 and has been a standing member of the NCI Experimental Therapeutics II (ET-2) and currently the Clinical Immunology and Immunotherapy II (C-II) study sections. As a Clinician Scientist, his mentorship is of particular importance as SCCC scientist seek to enhance cross talk between our post-PhD and post-MD Fellows in this Breast Cancer Translational Research. His research relevant to Breast Cancer includes the synthesis and testing of novel antibodyfusion proteins which target the HER2 breast cancer antigen, and can inhibit angiogenesis or augment immune response to breast cancer.